ClinicalTrials.gg
CompletedNCT00525824GRAVITYUpdated May 13, 2011Results posted

12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe

A Phase 3 interventional study of Rosuvastatin (Crestor) and Ezetimibe in Hypercholesterolemia, Coronary Heart Disease and Atherosclerosis, sponsored by AstraZeneca. Completed at 9 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-05-13.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,743
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 59 studies testing rosuvastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. rosuvastatin · Hypercholesterolemia.

Enrollment
11th of 57
1,743 · median 203
Started
2007
the only one that year
Phase 3
33 of 59
none open now
Registered
14th of 59
by date
Lead sponsor
25 of 59
AstraZeneca

Among the 59 studies testing rosuvastatin in Hypercholesterolemia, this one is the 11th largest by enrollment of the 57 interventional ones that give a count, is the only one that started in 2007, is one of 33 in phase 3, and was the 14th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 59 studies testing rosuvastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 59 studies testing rosuvastatin in Hypercholesterolemia as a file.
02

Study summary

The purpose of this study is to determine whether treatment of Rosuvastatin (CRESTOR™) or Simvastatin given as monotherapy or given in combination with Ezetimibe, will lower the Low Density Lipoprotein Cholesterol (LDL-C) in patients with Hypercholesterolaemia and Coronary Heart Disease (CHD) or a CHD Risk Equivalent, Atherosclerosis or a 10-year CHD Risk of >20%

03

Conditions studied

  • Hypercholesterolemia
  • Coronary Heart Disease
  • Atherosclerosis

Keywords

  • Hypercholesterolaemia
  • Coronary Heart Disease (CHD)
  • Atherosclerosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with with hypercholesterolaemia and CHD or a CHD risk equivalent, clinical evidence of atherosclerosis or a Framingham 10-year CHD risk score of >20
  • Patients will need to sign an before any visit procedures can be performed, including procedures for the optional genetic research and biomarker studies.
  • Patients must be 18 years or older and will be asked to stop taking any current cholesterol-lowering medications. Dietary counselling will be provided which will include an overview of the Therapeutic Lifestyle Change (TLC) diet the patients will be asked to follow

Exclusion criteria

Exclusion Criteria:

  • Use of lipid lowering drugs and other prohibited concomitant medications. History of statin-induced myopathy, or serious reaction to other HMG-CoA reductase inhibitors (statins), including rosuvastatin, simvastatin and/or a history of hypersensitivity to any components of ezetimibe.
  • Patients considered to be unstable by their physician after the following events:

a myocardial infarction, recent episode of unstable angina, myocardial revascularisation [percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass graft (CABG) surgery or another revascularisation procedure] or a (TIA) or stroke and patients awaiting a planned myocardial revascularisation

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,743 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks Combination Treatment

    Percent change in LDL-C = (Combination treatment value - Baseline value)/Baseline value\*100

    Time frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)

Secondary outcomes

  1. Percent Change in High-density Lipoprotein Cholesterol (HDL-C) After 6 Weeks Combination Treatment

    Percent change in HDL-C = (Combination treatment value - Baseline value)/Baseline value\*100

    Time frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)

  2. Percent Change in Total Cholesterol (TC) After 6 Weeks Combination Treatment

    Percent change in TC = (Combination treatment value - Baseline value)/Baseline value\*100

    Time frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)

  3. Percent Change in Triglycerides (TG) After 6 Weeks Combination Treatment

    Percent change in TG = (Combination treatment value - Baseline value)/Baseline value\*100

    Time frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)

  4. Percent Change in Non-high-density Lipoprotein Cholesterol (nonHDL-C) After 6 Weeks Combination Treatment

    Percent change in nonHDL-C = (Combination treatment value - Baseline value)/Baseline value\*100

    Time frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)

  5. Percent Change in Apolipoprotein B (ApoB) After 6 Weeks Combination Treatment

    Percent change in ApoB = (Combination treatment value - Baseline value)/Baseline value\*100

    Time frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)

  6. Percent Change in Apolipoprotein A1 (ApoA-1) After 6 Weeks Combination Treatment

    Percent change in ApoA-1 = (Combination treatment value - Baseline value)/Baseline value\*100

    Time frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)

  7. Percent Change in TC/HDL-C After 6 Weeks Combination Treatment

    Percent change in TC/HDL-C = (Combination treatment value - Baseline value)/Baseline value\*100

    Time frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)

  8. Percent Change in LDL-C/HDL-C After 6 Weeks Combination Treatment

    Percent change in LDL-C/HDL-C = (Combination treatment value - Baseline value)/Baseline value\*100

    Time frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)

  9. Percent Change in Non-HDL-C/HDL-C After 6 Weeks Combination Treatment

    Percent change in non-HDL-C/HDL-C = (Combination treatment value - Baseline value)/Baseline value\*100

    Time frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)

  10. Percent Change in ApoB/ApoA-1 After 6 Weeks Combination Treatment

    Percent change in ApoB/ApoA-1 = (Combination treatment value - Baseline value)/Baseline value\*100

    Time frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)

  11. Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) After 6 Weeks Combination Treatment

    Percent change in hs-CRP = (Combination treatment value - Baseline value)/Baseline value\*100

    Time frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)

  12. Percent Change in LDL-C After 6 Weeks Monotherapy

    Percent change in LDL-C = (Monotherapy treatment value - Baseline value)/Baseline value\*100

    Time frame: Mean of Weeks 4 and 6 on monotherapy (Last observation carried forward)

07

Results

Posted Oct 7, 2009

Participant flow

Eight hundred thirty-three patients (with hypercholesterolaemia and CHD or CHD risk equivalent, atherosclerosis or a 10-year CHD risk of \>20%) were randomized into the study, from 111 sites located in the United States (56), Peru (13), Netherlands (12), Colombia (8), Argentina (8), Brazil (6), Chile (4) and Lithuania (4).

Participant flow — Overall Study
MilestoneR10 to R10 + E10R20 to R20 + E10S40 to S40 + E10S80 to S80 + E10
Started214214202203
Completed195186183188
Not completed19281915
Withdrew: Adverse event71167
Withdrew: Withdrawal by subject5934
Withdrew: Lost to follow-up4240
Withdrew: Incorrect enrolment/mis-randomisation1212
Withdrew: Severe non-compliance0111
Withdrew: Safety reasons1010
Withdrew: Other1331

Outcome measures

PrimaryPercent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks Combination Treatment

Percent change in LDL-C = (Combination treatment value - Baseline value)/Baseline value\*100

Time frame:
Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)
Reported as:
Mean · Percentage
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks Combination Treatment
PercentageR10 to R10 + E10R20 to R20 + E10S40 to S40 + E10S80 to S80 + E10
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks Combination Treatment-59.7200 ± 14.1660-63.4800 ± 16.6970-55.2200 ± 15.7500-57.4200 ± 20.4660
SecondaryPercent Change in High-density Lipoprotein Cholesterol (HDL-C) After 6 Weeks Combination Treatment

Percent change in HDL-C = (Combination treatment value - Baseline value)/Baseline value\*100

Time frame:
Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)
Reported as:
Mean · Percentage
Percent Change in High-density Lipoprotein Cholesterol (HDL-C) After 6 Weeks Combination Treatment
PercentageR10 to R10 + E10R20 to R20 + E10S40 to S40 + E10S80 to S80 + E10
Percent Change in High-density Lipoprotein Cholesterol (HDL-C) After 6 Weeks Combination Treatment6.4100 ± 13.93407.4600 ± 16.35103.9200 ± 12.68304.3400 ± 12.6430
SecondaryPercent Change in Total Cholesterol (TC) After 6 Weeks Combination Treatment

Percent change in TC = (Combination treatment value - Baseline value)/Baseline value\*100

Time frame:
Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)
Reported as:
Mean · Percentage
Percent Change in Total Cholesterol (TC) After 6 Weeks Combination Treatment
PercentageR10 to R10 + E10R20 to R20 + E10S40 to S40 + E10S80 to S80 + E10
Percent Change in Total Cholesterol (TC) After 6 Weeks Combination Treatment-43.0000 ± 11.2080-46.6300 ± 12.8180-39.5600 ± 12.6640-41.7100 ± 15.1500
SecondaryPercent Change in Triglycerides (TG) After 6 Weeks Combination Treatment

Percent change in TG = (Combination treatment value - Baseline value)/Baseline value\*100

Time frame:
Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)
Reported as:
Mean · Percentage
Percent Change in Triglycerides (TG) After 6 Weeks Combination Treatment
PercentageR10 to R10 + E10R20 to R20 + E10S40 to S40 + E10S80 to S80 + E10
Percent Change in Triglycerides (TG) After 6 Weeks Combination Treatment-28.8500 ± 23.7090-35.0000 ± 23.9710-22.9500 ± 28.1390-25.8200 ± 26.6190
SecondaryPercent Change in Non-high-density Lipoprotein Cholesterol (nonHDL-C) After 6 Weeks Combination Treatment

Percent change in nonHDL-C = (Combination treatment value - Baseline value)/Baseline value\*100

Time frame:
Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)
Reported as:
Mean · Percentage
Percent Change in Non-high-density Lipoprotein Cholesterol (nonHDL-C) After 6 Weeks Combination Treatment
PercentageR10 to R10 + E10R20 to R20 + E10S40 to S40 + E10S80 to S80 + E10
Percent Change in Non-high-density Lipoprotein Cholesterol (nonHDL-C) After 6 Weeks Combination Treatment-54.6500 ± 13.6770-58.9100 ± 14.9320-49.9300 ± 14.7380-52.3700 ± 18.4290
SecondaryPercent Change in Apolipoprotein B (ApoB) After 6 Weeks Combination Treatment

Percent change in ApoB = (Combination treatment value - Baseline value)/Baseline value\*100

Time frame:
Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)
Reported as:
Mean · Percentage
Percent Change in Apolipoprotein B (ApoB) After 6 Weeks Combination Treatment
PercentageR10 to R10 + E10R20 to R20 + E10S40 to S40 + E10S80 to S80 + E10
Percent Change in Apolipoprotein B (ApoB) After 6 Weeks Combination Treatment-46.1100 ± 12.6280-49.5000 ± 13.8210-41.9500 ± 14.7500-44.1700 ± 17.1790
SecondaryPercent Change in Apolipoprotein A1 (ApoA-1) After 6 Weeks Combination Treatment

Percent change in ApoA-1 = (Combination treatment value - Baseline value)/Baseline value\*100

Time frame:
Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)
Reported as:
Mean · Percentage
Percent Change in Apolipoprotein A1 (ApoA-1) After 6 Weeks Combination Treatment
PercentageR10 to R10 + E10R20 to R20 + E10S40 to S40 + E10S80 to S80 + E10
Percent Change in Apolipoprotein A1 (ApoA-1) After 6 Weeks Combination Treatment3.8100 ± 13.04202.6800 ± 11.50201.4900 ± 9.68302.1300 ± 10.7410
SecondaryPercent Change in TC/HDL-C After 6 Weeks Combination Treatment

Percent change in TC/HDL-C = (Combination treatment value - Baseline value)/Baseline value\*100

Time frame:
Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)
Reported as:
Mean · Percentage
Percent Change in TC/HDL-C After 6 Weeks Combination Treatment
PercentageR10 to R10 + E10R20 to R20 + E10S40 to S40 + E10S80 to S80 + E10
Percent Change in TC/HDL-C After 6 Weeks Combination Treatment-45.5200 ± 13.2280-49.4600 ± 13.5750-41.2700 ± 13.0210-43.4500 ± 16.3430
SecondaryPercent Change in LDL-C/HDL-C After 6 Weeks Combination Treatment

Percent change in LDL-C/HDL-C = (Combination treatment value - Baseline value)/Baseline value\*100

Time frame:
Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)
Reported as:
Mean · Percentage
Percent Change in LDL-C/HDL-C After 6 Weeks Combination Treatment
PercentageR10 to R10 + E10R20 to R20 + E10S40 to S40 + E10S80 to S80 + E10
Percent Change in LDL-C/HDL-C After 6 Weeks Combination Treatment-61.4700 ± 15.5470-65.2500 ± 16.6800-57.1300 ± 14.7770-58.6600 ± 21.1300
SecondaryPercent Change in Non-HDL-C/HDL-C After 6 Weeks Combination Treatment

Percent change in non-HDL-C/HDL-C = (Combination treatment value - Baseline value)/Baseline value\*100

Time frame:
Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)
Reported as:
Mean · Percentage
Percent Change in Non-HDL-C/HDL-C After 6 Weeks Combination Treatment
PercentageR10 to R10 + E10R20 to R20 + E10S40 to S40 + E10S80 to S80 + E10
Percent Change in Non-HDL-C/HDL-C After 6 Weeks Combination Treatment-56.4200 ± 15.4150-60.8900 ± 15.5030-51.1100 ± 15.3800-53.5100 ± 20.2230
SecondaryPercent Change in ApoB/ApoA-1 After 6 Weeks Combination Treatment

Percent change in ApoB/ApoA-1 = (Combination treatment value - Baseline value)/Baseline value\*100

Time frame:
Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)
Reported as:
Mean · Percentage
Percent Change in ApoB/ApoA-1 After 6 Weeks Combination Treatment
PercentageR10 to R10 + E10R20 to R20 + E10S40 to S40 + E10S80 to S80 + E10
Percent Change in ApoB/ApoA-1 After 6 Weeks Combination Treatment-47.3900 ± 13.8690-50.2400 ± 14.2570-42.5400 ± 14.2480-44.7600 ± 17.8420
SecondaryPercent Change in High-sensitivity C-reactive Protein (Hs-CRP) After 6 Weeks Combination Treatment

Percent change in hs-CRP = (Combination treatment value - Baseline value)/Baseline value\*100

Time frame:
Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)
Reported as:
Mean · Percentage
Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) After 6 Weeks Combination Treatment
PercentageR10 to R10 + E10R20 to R20 + E10S40 to S40 + E10S80 to S80 + E10
Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) After 6 Weeks Combination Treatment107.1200 ± -99.0000-9.5300 ± -97.900015.0300 ± -91.50000.4200 ± -94.9000
SecondaryPercent Change in LDL-C After 6 Weeks Monotherapy

Percent change in LDL-C = (Monotherapy treatment value - Baseline value)/Baseline value\*100

Time frame:
Mean of Weeks 4 and 6 on monotherapy (Last observation carried forward)
Reported as:
Mean · Percentage
Percent Change in LDL-C After 6 Weeks Monotherapy
PercentageR10 to R10 + E10R20 to R20 + E10S40 to S40 + E10S80 to S80 + E10
Percent Change in LDL-C After 6 Weeks Monotherapy-46.4900 ± 13.1080-53.5900 ± 10.5030-40.8600 ± 12.4130-46.3500 ± 16.1880

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rosuvastatin 10 mg———
Rosuvastatin 20 mg———
Simvastatin 40 mg———
Simvastatin 80 mg———
Rosu 10 mg + Eze 10 mg———
Rosu 20 mg + Eze 10 mg———
Simva 40 mg + Eze 10 mg———
Simva 80 mg + Eze 10 mg———
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventRosuvastatin 10 mgRosuvastatin 20 mgSimvastatin 40 mgSimvastatin 80 mgRosu 10 mg + Eze 10 mgRosu 20 mg + Eze 10 mgSimva 40 mg + Eze 10 mgSimva 80 mg + Eze 10 mg
Angina unstableCardiac disorders0/2130/2120/1990/2032/2000/1913/1890/192
Cerebrovascular accidentNervous system disorders0/2132/2120/1990/2030/2000/1910/1890/192
Myocardial ischaemiaCardiac disorders0/2130/2120/1990/2030/2000/1911/1890/192
Fracture displacementInjury, poisoning and procedural complications0/2130/2120/1990/2030/2000/1911/1890/192
Non-Hodgkin's lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2130/2120/1990/2030/2000/1911/1890/192
Thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2130/2120/1990/2030/2000/1911/1890/192
Staphylococcal abscessInfections and infestations0/2130/2120/1990/2030/2001/1910/1890/192
AnaemiaBlood and lymphatic system disorders0/2130/2120/1990/2030/2000/1910/1891/192
Abdominal abscessInfections and infestations0/2130/2120/1990/2030/2000/1910/1891/192
DiverticulitisInfections and infestations0/2130/2120/1990/2030/2000/1910/1891/192
Most frequent other events
Showing 10 of 11
Most frequent other events
EventRosuvastatin 10 mgRosuvastatin 20 mgSimvastatin 40 mgSimvastatin 80 mgRosu 10 mg + Eze 10 mgRosu 20 mg + Eze 10 mgSimva 40 mg + Eze 10 mgSimva 80 mg + Eze 10 mg
MyalgiaMusculoskeletal and connective tissue disorders5/21310/2123/1997/2034/2005/1914/1893/192
NasopharyngitisInfections and infestations3/2133/2124/1993/2032/2005/1912/1893/192
HeadacheNervous system disorders4/2134/2125/1994/2033/2001/1911/1892/192
NauseaGastrointestinal disorders4/2135/2121/1991/2031/2003/1912/1891/192
DizzinessNervous system disorders1/2135/2121/1992/2031/2002/1913/1892/192
ArthralgiaMusculoskeletal and connective tissue disorders5/2134/2121/1994/2032/2000/1911/1892/192
InfluenzaInfections and infestations2/2131/2124/1991/2030/2004/1913/1890/192
Oedema peripheralGeneral disorders0/2130/2120/1990/2031/2000/1912/1894/192
BronchitisInfections and infestations1/2131/2124/1992/2033/2002/1912/1891/192
Upper respiratory tract infectionInfections and infestations1/2131/2124/1993/2032/2001/1913/1892/192

Baseline characteristics

Age Continuous
Age Continuous(years)R10 to R10 + E10R20 to R20 + E10S40 to S40 + E10S80 to S80 + E10Total
Mean62.2 ± 10.1461.8 ± 9.9361.9 ± 9.3762.1 ± 9.1762.0 ± 9.66
Sex: Female, Male
Sex: Female, Male(Participants)R10 to R10 + E10R20 to R20 + E10S40 to S40 + E10S80 to S80 + E10Total
Female91.000097.000097.000090.0000375.0
Male123.0000117.0000105.0000113.0000458.0
08

Study locations

9 sites
  • Research Site
    Brentwood, Tennessee, United States
  • Research Site
    Buenos Aires, Argentina
  • Research Site
    Sao Paulo, SP, Brazil
  • Research Site
    Santiago, Chile
  • Research Site
    Brentwood, Colombia
  • Research Site
    Brentwood, Lithuania
  • Research Site
    Zwinderen, Netherlands
  • Research Site
    Lima, San Isidro Lima, Peru
  • Research Site
    Brentwood, Venezuela
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2007
First posted
Sep 6, 2007
Start
Aug 2007
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Results first posted
Oct 7, 2009
Last update
May 13, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00525824
Lead sponsor
AstraZeneca
First posted
Sep 6, 2007
Start date
Aug 2007
Primary completion
Sep 2008
Completion
Sep 2008
Results posted
Oct 7, 2009
Last update
May 13, 2011

Study contacts

Christie M Ballantyne, MD FACP FACC
principal investigator · Centre for Cardiovascular Disease Prevention
Margareta Grind, MD PhD FFPM
study chair · Medicine and Sciences AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosuvastatin · Ezetimibe · Simvastatin

Start the discussion